Voyager appoints Robin Swartz as president and future CEO
Voyager Therapeutics appointed Robin Swartz as president from October 20, 2026, and she is expected to become CEO after Q1 2027 safety data.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Voyager Therapeutics has appointed Robin Swartz as president, effective October 20, 2026, according to TradingView, which cites filings with the SEC. She is expected to succeed Alfred W. Sandrock, Jr. as chief executive officer after initial clinical trial safety data arrives in the first quarter of 2027.
Sandrock will remain on the board of directors. Swartz is 56, has worked at Voyager since 2021, and has served as chief operating and chief business officer since November 2024, also taking the role of principal financial officer and treasurer in May 2026. She previously held senior positions at Genzyme and Sanofi Genzyme.
why it matters
The news mainly concerns the management structure of a single company. The leadership handover is tied to results from the VY1706 trial, so investors are likely to watch the safety data closely. The event is unlikely to have a broad effect on the market.
tags
instruments
sources
- Voyager names Robin Swartz President; to succeed Alfred Sandrock as CEO upon trial data — TradingView, 21 October 2026 at 12:13 UTC
- Voyager Therapeutics names Robin Swartz as successor to CEO Alfred Sandrock — Seeking Alpha, 21 October 2026 at 12:09 UTC
- Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027 — Reuters, 21 October 2026 at 12:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗